Home›Trial›NCT07265947
🔬NCT07265947Phase 2RECRUITING

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Study Summary

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Conditions
Low Grade Upper Tract Urothelial Carcinoma
Interventions / Drugs
Dabogratinib (TYRA-300) 60mgDabogratinib (TYRA-300) 80mgDabogratinib (TYRA-300) TBD
View on ClinicalTrials.gov ↗
Sponsor
TYRA
Tyra Biosciences
Precision Medicine
C59/100
Study Details
Enrollment230 participants
Primary Completion—
Lead SponsorTyra Biosciences, Inc
Data Retrieved2026-04-11 04:30:22.593382+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.